Loading clinical trials...
Loading clinical trials...
2-Hydroxybenzylamine (2-HOBA) to Prevent Early Recurrence of Atrial Fibrillation After Catheter- Based Ablation
Conditions
Interventions
2-Hydroxybenzylamine
Placebo
Locations
1
United States
Vanderbilt University Medical
Nashville, Tennessee, United States
Start Date
May 15, 2020
Primary Completion Date
January 30, 2022
Completion Date
January 30, 2023
Last Updated
November 21, 2024
NCT05147792
NCT06935591
NCT05963698
NCT03546374
NCT04947657
NCT06686485
Lead Sponsor
Vanderbilt University Medical Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions